GGrantIndex
← Search

Gene Targeting & Transgenic Mouse

$146,353P30FY2021CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

PROJECT SUMMARY ? GENE TARGETING AND TRANSGENIC FACILITY The Gene Targeting and Transgenic facility was founded over 28 years ago to assist AECC researchers in the generation of genetically modified mouse models of human disease. Initially, the Gene Targeting and Transgenic components operated as independent Shared Resources, however, following relocation to state-of- the-art laboratory space in the Price Center, the facilities were merged into a single Gene Targeting and Transgenic Shared Resource (GT&TF) In addition, a Gene Modification Service was implemented and integrated with the Facility to provide a complete service for the rapid and cost efficient generation of genetically modified mouse lines to all AECC investigators. The Transgenic component of the facility continues to generate, with high efficiency (~100% success rate), transgenic mouse strains through the introduction of DNA sequences, such as regular plasmid vectors or BAC clones, into the germ line by pronuclear injection or by lentivirus infection of fertilized oocytes. For each project, the facility supervisor consults with individual investigators and advises on transgene construct design, as well as making plasmids and sequence cassettes available to ensure suitability for expression in the mouse. The Gene Targeting component provided services for modification of the mouse genome through the use of CRISPR/Cas9 gene editing which was established during the current funding period. Although the vast majority of gene targeting projects are now conducted by CRISPR/Cas9, the facility continues to provide conventional gene targeting in embryonic stem (ES) cells and blastocyst injections upon request. Gene Targeting services include the generation of conventional knockout mouse lines, knock-in mouse lines and mouse lines with conditional alleles for the temporal and spatial ablation of genes. The facility has a high success rate (>95%) for obtaining gene targeted mouse lines. Finally, the services of the facility include the design and generation of simple and complex gene targeting vectors, electroporation and screening of embryonic stem cell lines as well as human and mouse cancer cell lines and the generation of chimeric mice by blastocyst injection. In addition, the facility offers mouse reproductive services for cryopreservation and re-derivation of transgenic and gene-targeted mouse lines as well as IVF services. Typically 25-30 investigators use this service each year with approximately 200 founder mice generated per year.

View original record on NIH RePORTER →